Form 4: ADC Therapeutics CEO Sells Shares for Tax Obligations

ADC Therapeutics CEO Ameet Mallik disposed of 233,146 common shares to cover tax withholding obligations related to vested restricted share units.

Summary

• Ameet Mallik, Chief Executive Officer and Director of ADC Therapeutics SA (ADCT), reported a disposition of common shares.
• The transaction occurred on December 6, 2025.
• 233,146 common shares were disposed of at a price of $3.29 per share.
• This disposition was made to satisfy tax withholding obligations in connection with the vesting of previously granted restricted share units.
• Following this transaction, Ameet Mallik beneficially owns 1,319,101 common shares directly.

Sentiment

Score: 5

Explanation: The transaction represents a non-discretionary disposition of shares to cover tax obligations upon the vesting of restricted share units, a common and expected event for executive compensation. It does not reflect a change in the company's operational performance or a discretionary sale by the insider.

Positives

• The vesting of restricted share units indicates that previously granted equity compensation is maturing, aligning executive interests with shareholder value.

Negatives

• A significant number of shares (233,146) were disposed of by the CEO, although for the non-discretionary purpose of tax withholding.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, as it is a report of a past insider transaction.

Industry Context

This filing is a routine insider transaction report (Form 4) detailing a disposition of shares for tax withholding purposes, which is a common occurrence across all publicly traded companies when executive equity compensation vests. It does not provide information directly related to broader industry trends or competitive landscape.

Comparison to Industry Standards

• The disposition of shares for tax withholding upon the vesting of restricted share units is a standard practice for executive compensation across industries and is not indicative of unique company or project performance.

Related Party Transactions

• Disposition of 233,146 common shares by CEO Ameet Mallik to ADC Therapeutics SA to satisfy tax withholding obligations related to vested restricted share units.

Stakeholder Impact

• Shareholders: The CEO's beneficial ownership decreased by 233,146 shares, but this is for tax purposes, not a discretionary sale, and is a routine part of equity compensation.
• Management: The CEO's equity compensation has vested, and tax obligations have been met.

Key Dates

Recommendation

This Form 4 details a non-discretionary disposition of shares by the CEO to cover tax withholding obligations upon the vesting of restricted share units. Such transactions are routine for executives receiving equity compensation and do not typically reflect a change in the company's operational performance or a discretionary vote of confidence (or lack thereof) by the insider. Therefore, it does not provide a basis for a change in investment recommendation.

Keywords

ADC Therapeutics, ADCT, Ameet Mallik, Form 4, Insider Transaction, Share Disposition, Tax Withholding, Restricted Share Units, CEO, Director